P
Pegasus Biologics
HugeDomains.com - PegasusBio.com is for sale (Pegasus Bio)
About Pegasus Biologics
Pegasus Biologics, Inc. was a privately held medical device company established in 2003, with its headquarters in Irvine, California. The company was founded by France Dixon Helfer, who also served as its President. Pegasus Biologics focused on developing and commercializing bio-implants for soft tissue repair, primarily targeting the orthopedic, spine, neurosurgery, and wound care markets.
The firm's business model revolved around the manufacture and sale of its proprietary collagen-based products to address needs in surgical and wound management settings. A significant part of its strategy involved leveraging patented technologies for the stabilization and sterilization of biologic tissue and collagen scaffolds. This allowed the company to create products with tailored mechanical properties, designed for either durability or rapid tissue integration, a key differentiator in the market. The company's product line included the OrthADAPT® Bioimplant, a Type I collagen scaffold for reinforcing soft tissues like tendons and ligaments during surgical repairs, and the Unite® Biomatrix, a collagen dressing for advanced wound management. These products saw considerable adoption, with OrthADAPT™ being used in over 2,500 patient treatments within about a year of its launch and receiving CE Mark certification in 2007, enabling its sale in the European market.
Throughout its operation, Pegasus Biologics secured approximately $31.9 million in funding from investors including Affinity Capital Management, Frazier Healthcare Partners, ONSET Ventures, Pinnacle Ventures, and Three Arch Partners. The company demonstrated notable growth, expanding its manufacturing facilities in Irvine to nearly 21,000 square feet by 2008 to meet increasing product demand. However, after facing challenges in securing new financing, Pegasus Biologics ceased operations. In July 2009, its assets were acquired by Synovis Life Technologies, Inc. for $12.1 million in cash. Synovis continued the manufacturing operations in Irvine, integrating the Pegasus products into its own portfolio.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Mar 2024 | $250K | — | Undisclosed | — |
| GRANTOther financing | Dec 2022 | $220K | — | Undisclosed | — |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Pegasus Biologics in the Irvine ecosystem
The Pegasus Biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Three Arch Partners
Frazier Healthcare PartnersLife Science Angels
Series B and later2 investors entered at this stage
- OVOnset Ventures
Affinity Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pegasus Biologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pegasus Biologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









